Profile data is unavailable for this security.
About the company
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Company’s drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
- Revenue in JPY (TTM)428.36m
- Net income in JPY-812.41m
- Incorporated1999
- Employees21.00
- LocationD.Western Therapeutics Institute Inc1-18-11, NishikiNAGOYA-SHI 460-0003JapanJPN
- Phone+81 522188785
- Fax+81 522021866
- Websitehttps://dwti.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PhoenixBio Co Ltd | 1.79bn | 113.89m | 1.93bn | 65.00 | 24.09 | 1.09 | 13.91 | 1.08 | 19.88 | 19.88 | 401.02 | 440.43 | 0.6625 | 1.52 | 7.19 | 27,575,230.00 | 4.21 | -7.00 | 6.09 | -8.77 | 67.48 | 65.55 | 6.35 | -12.08 | 4.19 | -- | 0.2199 | -- | 60.33 | 18.67 | 227.16 | -- | 14.18 | -- |
| Modalis Therapeutics Corp | 0.00 | -2.39bn | 2.91bn | 37.00 | -- | 1.91 | -- | -- | -76.74 | -76.74 | 0.00 | 41.39 | 0.00 | -- | -- | 0.00 | -92.78 | -29.19 | -99.33 | -30.02 | -- | -- | -- | -597.35 | 9.84 | -- | 0.2301 | -- | -100.00 | -- | 11.50 | -- | 135.50 | -- |
| Atect Corp | 3.20bn | 114.29m | 3.00bn | 96.00 | 26.19 | 1.43 | 6.52 | 0.9388 | 25.85 | 25.85 | 723.76 | 474.92 | 0.5713 | 3.22 | 6.85 | 33,330,020.00 | 2.04 | 2.03 | 2.83 | 2.78 | 44.68 | 47.69 | 3.57 | 3.84 | 0.7119 | -- | 0.546 | 29.40 | -4.03 | 2.10 | -6.37 | 14.01 | -23.31 | 0.00 |
| Muromachi Chemicals Inc | 6.12bn | 216.69m | 3.03bn | 205.00 | 13.84 | 1.40 | 8.63 | 0.4951 | 53.45 | 53.45 | 1,503.34 | 527.87 | 1.20 | 3.83 | 3.75 | 29,862,370.00 | 4.23 | -- | 6.84 | -- | 28.31 | -- | 3.54 | -- | 1.45 | 26.20 | 0.4483 | -- | 10.74 | -- | -43.83 | -- | -- | -- |
| Ribomic Inc | 62.64m | -979.09m | 3.14bn | 25.00 | -- | 0.8566 | -- | 50.13 | -27.45 | -27.45 | 1.76 | 100.39 | 0.0144 | -- | 1.22 | 2,505,440.00 | -22.56 | -32.10 | -24.05 | -33.30 | -- | -- | -1,563.14 | -1,688.50 | 18.53 | -- | 0.00 | -- | -18.47 | 0.3809 | 1.88 | -- | 10.04 | -- |
| D.Western Therapeutics Institute Inc | 428.36m | -812.41m | 3.53bn | 21.00 | -- | 2.76 | -- | 8.25 | -25.45 | -25.45 | 13.48 | 39.83 | 0.1607 | 0.4389 | 2.98 | 20,398,290.00 | -31.09 | -13.06 | -33.75 | -14.36 | 91.44 | 94.29 | -193.39 | -72.51 | 10.57 | -- | 0.4089 | -- | -4.40 | 7.90 | -89.07 | -- | 7.08 | -- |
| Kringle Pharma Inc | 70.58m | -865.79m | 3.74bn | 13.00 | -- | 1.53 | -- | 52.96 | -158.59 | -158.59 | 12.88 | 374.93 | 0.024 | -- | 0.7308 | 5,428,846.00 | -29.38 | -19.00 | -30.70 | -20.23 | -- | -- | -1,226.76 | -156.51 | 26.45 | -1,190.33 | 0.00 | -- | -82.33 | -- | -157.41 | -- | -- | -- |
| Human Metabolome Technologies Inc | 1.32bn | 282.64m | 3.82bn | 57.00 | 13.49 | 2.16 | 10.46 | 2.89 | 47.83 | 47.83 | 223.67 | 299.17 | 0.6302 | 14.23 | 4.74 | 23,186,330.00 | 13.48 | -- | 16.73 | -- | 65.03 | -- | 21.39 | -- | 4.27 | 151.90 | 0.1103 | -- | 6.21 | -- | 6.71 | -- | -- | -- |
| FunPep Co Ltd | 530.00k | -933.42m | 3.82bn | 15.00 | -- | 1.55 | -- | 7,213.76 | -40.11 | -40.11 | 0.0225 | 94.97 | 0.0002 | -- | -- | 35,333.33 | -34.04 | -27.10 | -35.68 | -28.75 | -- | -- | -176,116.20 | -815.82 | 25.95 | -1,765.73 | 0.00 | -- | -50.33 | -72.80 | 20.39 | -- | -13.14 | -- |
| Kubota Pharmaceutical Holdings Co Ltd | 39.89m | -1.49bn | 4.00bn | 12.00 | -- | 1.50 | -- | 100.21 | -26.80 | -26.80 | 0.7175 | 47.21 | 0.0107 | 0.5317 | 14.77 | 3,323,917.00 | -40.06 | -36.51 | -43.86 | -39.47 | 70.48 | -- | -3,734.55 | -13,528.87 | 10.01 | -- | 0.0512 | -- | 383.24 | -- | 26.11 | -- | 24.38 | -- |
| OncoTherapy Science, Inc. | 901.22m | -1.19bn | 4.03bn | 60.00 | -- | 5.97 | -- | 4.47 | -5.77 | -5.77 | 4.36 | 3.01 | 0.7589 | 5.31 | 15.74 | 15,020,330.00 | -100.44 | -50.21 | -132.58 | -55.41 | -9.03 | -- | -132.35 | -331.97 | 3.29 | -258.18 | 0.00 | -- | -1.63 | 39.97 | 56.50 | -- | -57.92 | -- |
| Perseus Proteomics Inc | 96.22m | -1.12bn | 4.07bn | 24.00 | -- | 2.53 | -- | 42.32 | -95.57 | -95.57 | 8.18 | 131.49 | 0.0424 | 1.82 | 11.22 | 4,009,083.00 | -49.52 | -33.51 | -51.65 | -34.95 | 89.01 | 93.09 | -1,168.66 | -470.63 | 17.58 | -- | 0.00 | -- | 30.96 | -20.89 | -31.38 | -- | 228.18 | -- |
| BrightPath Biotherapeutics Co Ltd | 118.00k | -1.21bn | 4.24bn | 32.00 | -- | 5.03 | -- | 35,970.15 | -19.27 | -19.27 | 0.0019 | 11.92 | 0.00007 | -- | 0.0423 | 3,687.50 | -71.34 | -42.65 | -89.42 | -44.49 | -433.05 | 57.16 | -1,028,827.00 | -4,430.66 | -- | -875.45 | 0.3929 | -- | -65.73 | -56.89 | -0.0971 | -- | -56.39 | -- |
| Immuno-Biological Laboratories Co., Ltd. | 788.12m | -192.71m | 4.28bn | 60.00 | -- | 3.90 | -- | 5.44 | -20.69 | -20.69 | 84.62 | 118.02 | 0.5144 | 0.8788 | 3.78 | 13,135,280.00 | -12.58 | -15.11 | -14.85 | -17.61 | 62.06 | 56.66 | -24.45 | -50.04 | 3.49 | 0.494 | 0.1774 | -- | 22.71 | 0.9405 | -11.97 | -- | -- | -- |
| Renascience Inc | 191.32m | -331.66m | 4.44bn | 3.00 | -- | 2.70 | -- | 23.19 | -26.09 | -26.09 | 15.05 | 129.22 | 0.0851 | -- | -- | 63,772,000.00 | -14.74 | -- | -15.49 | -- | 85.75 | -- | -173.36 | -- | -- | -- | 0.1782 | -- | -27.84 | -- | -32.05 | -- | -- | -- |
| MEDRx Co Ltd | 29.53m | -932.90m | 4.63bn | 22.00 | -- | 2.25 | -- | 156.74 | -27.24 | -27.24 | 0.8492 | 50.17 | 0.0171 | 0.2606 | 1.22 | 1,342,455.00 | -54.07 | -58.15 | -58.45 | -62.23 | 91.87 | 95.70 | -3,158.72 | -1,526.17 | 17.75 | -- | 0.00 | -- | -50.35 | 28.60 | 16.04 | -- | -55.29 | -- |
Data as of May 02 2024. Currency figures normalised to D.Western Therapeutics Institute Inc's reporting currency: Japanese Yen JPY
